Algeta ASA (ALGETA.OL)
21 May 2013
|Market Cap (Mil.):||kr9,345.26|
|Shares Outstanding (Mil.):||42.57|
FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.
Earnings vs. Estimates
Analyst Research Reports
Provider: Edison Investment Research
Algeta ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.